Point Therapeutics reports longer survival from use of talabostat against lung cancer

New York, Nov. 1 - Point Therapeutics, Inc. said that evaluation of additional data from its phase 2 trials of talabostat in combination with docetaxel against non-small cell lung cancer showed an increase in median progression-free survival over the previously reported interim results of 4.0 months.

The company said the results further support its recently begun phase 3 program because progression-free survival is the primary goal of that study.

Point will make a poster presentation of the results at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on Nov. 16.

The company is also conducting a phase 2 program to evaluate talabostat in metastatic melanoma.

This program has two trials, a talabostat trial and a combination trial of talabostat with cisplatin.

In the single agent trial, it has been determined that there are no additional responders beyond those previously reported, Point said. However, the median survival results are generally consistent with those of the currently approved chemotherapy standard of care. In addition, talabostat has demonstrated a more favorable adverse event profile in this study and is orally administered while the current standard of care is administered intravenously.

The additional metastatic melanoma phase 2 trial results will be the subject of a poster presentation at the International Society for the Biological Therapy of Cancer Annual Meeting on Nov. 12.

"We are pleased with the results from our clinical development programs, including that our three complete responders - two from our lung cancer trial and one from our single agent melanoma trial - continue to be complete responders," said Don Kiepert, president and chief executive officer of Point Therapeutics, in a news release.

"In addition to implementing our phase 3 non-small cell lung cancer program, we continue to evaluate our phase 2 metastatic melanoma program and expect to announce by year-end whether or not we believe the results merit pursuing a phase 3 program.

"It is, however, unlikely that the company would initiate a Phase 3 metastatic melanoma trial without a partner."

Point is a Boston-based biopharmaceutical company developing a family of dipeptidyl peptidase inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.